20600-29-7

Usage

Physical State

Clear, colorless liquid

Odor

Faint aromatic

Usage

Manufacturing of pharmaceuticals, herbicides, and other organic chemicals

Structural Feature

Brominated derivative of benzene

Attachment

Phenoxy methyl group attached to the third carbon atom

Role

Intermediate in the synthesis of various compounds

Application

Building blocks in organic chemistry

Reactivity

Ability to undergo various substitution reactions

Value

Production of a wide range of organic compounds

InChI:InChI=1/C13H11BrO/c14-12-6-4-5-11(9-12)10-15-13-7-2-1-3-8-13/h1-9H,10H2

Upstream product

• 456-43-9 1-bromo-3-(fluoromethyl)benzene 
• 139-02-6 sodium phenoxide 
• 932-77-4 3-bromobenzyl chloride 
• 108-95-2 phenol 
• 15852-73-0 (3-Bromophenyl)methanol 
• 88284-48-4 2-(trimethylsilyl)phenyl trifluoromethanesulfonate 
• 823-78-9 meta-bromobenzyl bromide 

Downstream Products

• 31719-75-2 3-phenoxymethylbenzoic acid 
• 139-66-2 diphenyl sulfide 
• 13865-48-0 3-methylphenyl phenyl sulfide 
• 946-80-5 (benzyloxy)benzene 
• 211615-07-5 (3-bromobenzyl)(phenyl)sulfane 
• 94306-40-8 Phenyl-(4-phenylmercapto-benzyl)-sulfid 
• 75954-35-7 phenyl p-bromobenzyl sulfide 
• 1423148-50-8 2-fluoro-4-methyl-3'-(phenoxymethyl)-5-((2,2,2-trifluoroethyl)sulfinyl)-1,1'-biphenyl 
• 1423148-49-5 (6-fluoro-4-methyl-3'-(phenoxymethyl)-[1,1'-biphenyl]-3-yl)(2,2,2-trifluoroethyl)sulfane 

Relevant academic research and scientific papers

From insertion to multicomponent coupling: Temperature dependent reactions of arynes with aliphatic alcohols

The temperature dependent selectivity switch in the reaction of arynes with aliphatic alcohols in THF has been reported. At -20°C, arynes smoothly insert into the O-H bond of alcohols to form alkyl aryl ethers. Interestingly, at 60°C, a highly selective multicomponent coupling occurs with the solvent THF acting as the nucleophilic trigger affording (4-(alkoxy)butoxy)arenes.

Novel arylalkenylpropargylamines as neuroprotective, potent, and selective monoamine oxidase B inhibitors for the treatment of Parkinson's disease

To develop novel neuroprotective agents, a library of novel arylalkenylpropargylamines was synthesized and tested for inhibitory activities against monoamine oxidases. From this, a number of highly potent and selective monoamine oxidase B inhibitors were identified. Selected compounds were also tested for neuroprotection in in vitro studies with PC-12 cells treated with 6-OHDA and rotenone, respectively. It was observed that some of the compounds tested yielded a marked increase in survival in PC-12 cells treated with the neurotoxins. This indicates that these propargylamines are able to confer protection against the effects of the toxins and may also be considered as novel disease-modifying anti-Parkinsonian agents, which are much needed for the therapy of Parkinson's disease.

NEW ARYLALKENYLPROPARGYLAMINE DERIVATIVES EXHIBITING NEUROPROTECTIVE ACTION FOR THE TREATMENT OF NEURODEGENERATIVE DISEASES

The invention relates to novel arylalkenylpropargylamine derivatives of general formula (I) or enantiomers or diastereomers thereof or salts, optionally pharmaceutically acceptable salts, or solvates of any of these. The compounds can be used in treating or preventing a disease or condition in a mammal related to monoamine oxidase dysfunction, especially in neurodegenerative diseases, e.g. Parkinson's disease, Alzheimer's disease or Huntington's disease.